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Historically, recombinant membrane protein production has been a major challenge meaning that many
fewer membrane protein structures have been published than those of soluble proteins. However, there
has been a recent, almost exponential increase in the number of membrane protein structures being
deposited in the Protein Data Bank. This suggests that empirical methods are now available that can
ensure the required protein supply for these difficult targets. This review focuses on methods that are
available for protein production in yeast, which is an important source of recombinant eukaryotic mem-
brane proteins. We provide an overview of approaches to optimize the expression plasmid, host cell and
culture conditions, as well as the extraction and purification of functional protein for crystallization trials
in preparation for structural studies.
 2015 Published by Elsevier Inc.ylamino-
anoside;
orescent1. Recombinant membrane protein production in yeast
The first crystal structures of mammalian membrane proteins
derived from recombinant sources were solved in 2005 using pro-
tein that had been produced in yeast cells: the rabbit Ca2+-ATPase,
SERCA1a, was overexpressed in Saccharomyces cerevisiae [1] and
the rat voltage-dependent potassium ion channel, Kv1.2 was pro-
duced in Pichia pastoris [2] (Fig. 1a and e). Since then, several other
host cells have been used for eukaryotic membrane protein pro-
duction including Escherichia coli, baculovirus-infected insect cells
and mammalian cell-lines [3]. Whilst all host systems have advan-
tages and disadvantages, yeasts have remained a consistently-
popular choice in the eukaryotic membrane protein field [4,5]. As
microbes, they are quick, easy and cheap to culture; as eukaryotes
they are able to post-translationally process eukaryotic membrane
proteins. Very recent crystal structures of recombinant transmem-
brane proteins produced in yeast include those of human aqua-
porin 2, chicken bestrophin-1, the human TRAAK channel, human
leukotriene C4 synthase, an algal P-glycoprotein homologue and
mouse P-glycoprotein using P. pastoris-derived samples; thestructures of the Arabidopsis thaliana NRT1.1 nitrate transporter,
a fungal plant pathogen TMEM16 lipid scramblase and the yeast
mitochondrial ADP/ATP carrier were solved using recombinant
protein produced in S. cerevisiae (Fig. 1b–d, f–k).
Despite these successes (as well as others using recombinant
protein produced in bacteria, insect cells and mammalian cell-
lines; see http://blanco.biomol.uci.edu/mpstruc/), the overall rate
of progress in membrane protein structural biology has, until very
recently, been markedly slower than that in the soluble protein
field [6]. However, recent experimental breakthroughs mean that
the gap is set to narrow. For example, the use of stabilizing
mutants has had a revolutionary impact on increasing the crystal-
lization propensity of some membrane protein targets [7], while
incorporating fusion partner proteins such as T4 lyzozyme (T4L)1
[8] has been particularly important in structural studies of G
protein-coupled receptors (GPCR). From the perspective of the host, maltose
an; SMA,
unfolded
lution.
(c) TMEM16 (4WIS; 2014) (a) Ca2+-ATPase, SERCA1a 
(structure modelled on 1T5S) 
Crystal structures solved using recombinant proteins produced in S. cerevisiae
(b) NRT1.1 (4CL4; 2014)
(e) Kv1.2 (2A79; 2005) (f) Aquaporin 2 (4NEF; 2014)
Crystal structures solved using recombinant proteins produced in P. pastoris
(h) TRAAK (4WFF; 2014)
(i) Leukotriene C4 synthase (4JCZ; 2014)
(d) ADP/ATP carrier (4C9G; 2014) 
(k) P-glycoprotein (4Q9H; 2015)(j) P-glycoprotein homologue (3WME; 2014)
(g) Bestrophin-1 (4RDQ; 2014)
Fig. 1. Recombinant transmembrane proteins produced in yeast, for which crystal structures were published in 2014 and 2015; the first such structures, published in 2005,
are also shown. The name of the protein and the host cell used in its recombinant production are given, together with the PDB code and publication year. Structural images,
with the orientations shown, were downloaded directly from the PDB website (http://www.pdb.org/pdb/home/home.do) on 24th September 2015; protein chains are
coloured from the amino-terminus to the carboxy-terminus using a spectral colour gradient. (a) The structure of recombinant Ca2+-ATPase, SERCA1a, produced in S. cerevisiae
and published in 2005 [1], was not deposited in the PDB; the authors concluded that the structure of the yeast-expressed protein represents in full the native rabbit
(Oryctolagus cuniculus) protein (PDB code of the native protein: 1T5S). (b) The structure of the A. thaliana NRT1.1 nitrate transporter at 3.7 Å (PDB code: 4CL4; [18]) was solved
using a fusion protein with carboxy-terminal GFP and hexahistidine tags that had been produced in S. cerevisiae. (c) The structure of TMEM16 (from the plant pathogen,
Nectria haematococca) at 3.30 Å (PDB code: 4WIS; [94]) was solved using protein produced in S. cerevisiae following expression screening of more than 80 constructs; the
protein was produced as a fusion with a cleavable tag comprising enhanced-GFP and a decahistidine sequence. (d) The structure of the S. cerevisiae mitochondrial ADP/ATP
carrier at 2.49 Å (PDB code: 4C9G; [111]) was solved using a fusion protein with an amino-terminal histidine tag and a factor Xa cleavage site produced in S. cerevisiae. (e) The
structure of Kv1.2 at 2.9 Å (PDB code: 2A79; [2]) was solved using a recombinant rat (Rattus norvegicus) N207Q mutant with an amino-terminal octahistidine tag and TEV
protease cleavage site; this construct was co-expressed with the b2 channel b subunit from rat brain in P. pastoris. (f) The structure of the Homo sapiens aquaporin 2 water
channel was solved to 2.75 Å (PDB code: 4NEF; [112]) using recombinant protein produced in P. pastoris following codon optimization of the corresponding gene sequence. (g)
The structure of bestrophin-1 at 2.85 Å (PDB code: 4RDQ; [95]) was solved after screening 30 orthologues for expression in P. pastoris; the recombinant protein comprised
amino acids 1–405 of chicken (Gallus gallus) bestrophin-1 followed by an affinity tag (QGQQF) that is recognized by an anti-tubulin antibody. (h) The structure of the H.
sapiens TRAAK K+ channel at 2.5 Å (PDB code: 4WFF; [113]) was solved using protein produced in P. pastoris as an EGFP-decahistidine fusion protein with a carboxy-terminal
truncation and all N-linked glycosylation sites removed. (i) The structure of the H. sapiens leukotriene C4 synthase at 2.75 Å (PDB code: 4JCZ; [114]) was solved using protein
produced in P. pastoriswith a hexahistidine tag. (j) The structure of a P-glycoprotein homologue from Cyanidioschyzon merolae at 2.75 Å (PDB code: 3WME; [115]) was solved
using protein produced in P. pastoris with a carboxy-terminal decahistidine tag. (k) The structure of P-glycoprotein at 3.4 Å (PDB code: 4Q9H; [116]) was solved using a
glycosylation-deficient (mutations at N83, N87and N90) Mus musculus amino acid sequence encompassing a carboxy-terminal hexahistidine tag.
2 S.J. Routledge et al. /Methods xxx (2015) xxx–xxxcell, our improved understanding of cellular pathways controlling
translation and protein folding, and how they influence functional
recombinant protein yields, means it is now possible to select (or
even design) better expression strains; this knowledge has also
allowed a more strategic approach to cell culture in order to
maximise the productivity of each cell [3]. Finally, new methods
for extracting and solubilizing membrane proteins from the cell
membrane using styrene maleic anhydride (SMA) co-polymers have
enabled traditional detergents to be circumvented [9,10]. The
benefits of this approach include improved thermostability of the
solubilized protein and retention of protein–lipid interactions thatPlease cite this article in press as: S.J. Routledge et al., Methods (2015), http://are normally disrupted during detergent-extraction [11]. This review
focuses on current approaches to optimizing expression plasmids,
yeast strains and culture conditions, as well as the extraction and
purification of functional membrane proteins for crystallization
trials (and subsequent structural studies) using detergents and
SMA co-polymers.
2. Choice of yeast species: S. cerevisiae or P. pastoris?
Over 1500 species of yeast are known, but only very few of
them have been employed as host organisms for the productiondx.doi.org/10.1016/j.ymeth.2015.09.027
S.J. Routledge et al. /Methods xxx (2015) xxx–xxx 3of recombinant proteins [12]. The two most widely used for recom-
binant membrane protein production are S. cerevisiae and P. pas-
toris. These single-celled, eukaryotic microbes grow quickly in
complex or defined media (doubling times are typically 2.5 h in
glucose-containing media) in formats ranging from multi-well
plates to shake flasks and bioreactors of various sizes [12]. P. pas-
toris has the advantage of being able to grow to very high cell den-
sities (>100 g/L dry cell weight; >500 OD600 units/mL [5]) and
therefore has the potential to produce large amounts of recombi-
nant membrane protein for structural analysis (Fig. 1e–k). This
yeast has also been important in generating high-resolution GPCR
crystal structures such as the adenosine A2A [13] and the histamine
H1 [14] receptors. However, because it is a strictly aerobic
organism, the full benefits of P. pastoris are achievable only if it is
cultured under highly-aerated conditions; this is usually only
possible in continuously-stirred tank bioreactors.
S. cerevisiae has the advantage that its genetics are better under-
stood (http://www.yeastgenome.org/) and that it is supported by a
more extensive literature than P. pastoris. This has led to the devel-
opment of a much wider range of tools and strains for improved
membrane protein production (see Section 4). Consequently,
projects requiring specialized strains may benefit from using
S. cerevisiae as the host. Notably, the structure of the histamine
H1 receptor was obtained from protein produced in P. pastoris,
although initial screening to define the best expression construct
was performed in S. cerevisiae [15]. This is presumably because of
the greater range of molecular biological tools available for
S. cerevisiae at the screening stage, coupled with the superior yield
characteristics of P. pastoris when cultured at larger scale in biore-
actors. In principle, many of the tools established for S. cerevisiae
could be transferred to P. pastoris (for which a genome sequence
was published in 2009 [16]) combining the strengths of both yeast
species, although such work would be time-consuming. In our lab-
oratory, we often start with P. pastoris and, if the production is not
straightforward, turn to S. cerevisiae to troubleshoot thereby
benefitting from the best attributes of the two hosts [12].3. Optimization of the yeast expression plasmid
Having decided which yeast species will be used as the recom-
binant host, a suitable expression plasmid needs to be selected or
designed. Table 1 lists examples of common plasmids that are used
for recombinant protein production in S. cerevisiae and P. pastoris,
while Sections 3.1–3.3 briefly review three key elements of such
plasmids: the promoter; the nature of any tags and the codon
sequence.
Typically, episomal plasmids are used for expression in S. cere-
visiae, but the expression cassette is integrated into the genome of
P. pastoris. These continuing preferences may have resulted from
the replication of early successes using particular plasmid/species
combinations. Since the P. pastoris system depends upon very
strong promoters, only a few copies of the gene (as typicallyTable 1
Examples of commonly-used S. cerevisiae and P. pastoris expression plasmids.
Yeast Plasmid Selection marker Tag P
S. cerevisiae pYES2 URA3 None P
pVTU260 URA3 His6 P
P. pastoris pPICZ Zeocin His6e P
pGAPZ Zeocin His6e P
pBGP1 Zeocin None P
a https://tools.lifetechnologies.com/content/sfs/manuals/pyes2_man.pdf.
b http://web.uni-frankfurt.de/fb15/mikro/euroscarf/data/pVTU260.html; https://www
c https://tools.lifetechnologies.com/content/sfs/manuals/ppicz_man.pdf; plasmids con
d https://tools.lifetechnologies.com/content/sfs/manuals/pgapz_man.pdf; plasmids con
e These plasmids also contain a c-myc epitope tag.
Please cite this article in press as: S.J. Routledge et al., Methods (2015), http://present in stably-integrated strains) are required to obtain suffi-
cient levels of mRNA. In contrast, in S. cerevisiae, the promoter
can be 10- to 100-fold weaker so the use of episomal plasmids with
high copy numbers is advantageous; episomal plasmids are avail-
able for P. pastoris, but are not yet widely used in structural biology
projects.
Auxotrophic markers are routinely used in S. cerevisiae plasmids
to select for successfully-transformed yeast cells. Notably, the yield
of the recombinant insulin analogue precursor protein was
increased sevenfold simply by using the selection marker URA3
instead of LEU2 [17]. Truncations in the promoters of auxotrophic
marker genes can further increase recombinant protein yields: by
decreasing the promoter length, transcription of the marker gene
on the plasmid is reduced and the cell compensates by increasing
the plasmid copy number [17]. A truncated LEU2 promoter was
recently used to increase the yields of nine different transporters,
including NRT1.1 [18] (Fig. 1b).
3.1. The promoter – constitutive or inducible?
Most recombinant expression systems employed in structural
biology pipelines depend upon strong, inducible promoters to
drive high rates of mRNA synthesis. For example, the strong
S. cerevisiae promoter, PGAL1, is induced with galactose while PAOX1
(a very strong P. pastoris promoter) is induced with methanol [5].
In choosing a strong promoter, the idea is that transcription should
not be rate limiting. However, high mRNA synthesis rates may be
countered by high rates of mRNA degradation [19]. Moreover, evi-
dence from prokaryotic expression systems suggests that acquired
mutations that lower promoter efficiency lead to improved func-
tional yields of membrane proteins for some, but not all, targets
[20]. In a separate study, a series of E. coli strains that had been
evolved to improve their yield characteristics were found to have
a mutation in the hns gene, which has a role in transcriptional
silencing [21]. Together, these results support an emerging view
that a suitable balance between mRNA and protein synthesis rates
is desirable, although how this might be achieved in practice is not
yet understood; one possibility might be a system based on slow,
constitutive expression [22].
It has been proposed that the ideal inducible system would
completely uncouple cell growth from recombinant synthesis,
which requires the host cell to remain metabolically capable of
transcription and translation in a growth-arrested state. In this sce-
nario, all metabolic fluxes would be diverted to the production of
recombinant protein [23]. While this approach is yet to be demon-
strated for membrane protein production in yeast cells, soluble
chloramphenicol acetyltransferase was produced to more than
40% of total cell protein in E. coli [24] suggesting that this may
be a strategy worth exploring in yeast. Indeed, growth rates often
(but not always) decline dramatically upon induction of yeast cul-
tures, in part achieving this state.
When wild-type P. pastoris cells were cultured in methanol, it
was found that a higher proportion of the total mRNA pool wasromoter Episomal or integrative Supplier/reference
GAL1; Inducible Episomal Invitrogena
ADH1; Constitutive Episomal Euroscarfb
AOX1; Inducible Integrative Invitrogenc
GAP; Constitutive Integrative Invitrogend
GAP; Constitutive Episomal [106]
.addgene.org/63682/.
taining a 50 a mating factor pre-pro secretion signal sequence are also available.
taining a 50 a mating factor pre-pro secretion signal sequence are also available.
dx.doi.org/10.1016/j.ymeth.2015.09.027
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highly translated) compared to the same cells cultured in any other
non-inducing growth condition [25]. This observation suggests
that high recombinant protein yields in methanol-grown cells are
due not just to promoter strength, but also to the global response
of P. pastoris to growth on methanol [25]. However, PAOX1-driven
expression is leaky; the recent characterization of pre-induction
expression under the control of PAOX1 [26] indicates that the uncou-
pling of growth and protein synthesis in P. pastoris cells has not yet
been achieved. The response of a series of inducible S. cerevisiae
promoters to different carbon sources has also been studied [22];
this type of careful analysis of promoter expression patterns now
opens up opportunities for dynamic regulation of recombinant
protein production in S. cerevisiae.
3.2. Tags and other fusion partners
In addition to the open reading frame (ORF) of the gene of inter-
est, a typical expression plasmid will usually incorporate a number
of other sequences in its expression cassette. The S. cerevisiae
a-mating factor signal sequence is a common addition to commer-
cial expression plasmids (Table 1) because it is believed to correctly-
target recombinantmembrane proteins to the yeast membrane. For
example, its presence had a positive impact on the yield of the
mouse 5-HT5A serotonin receptor [27] but dramatically reduced
expression of the histamine H1 receptor [28]. Alternative signal
sequences have been used (albeit much less frequently) such as
the STE2 leader sequence of the fungal GPCR, Ste2p [29].
Many expression plasmids contain tags as part of their DNA
sequence (Table 1), and it is straightforward to add a range of
others [30] by gene synthesis or polymerase chain reaction.
Frequently-used tags for recombinant membrane proteins are
polyhistidine (hexa-, octa- and decahistine tags are all common),
green fluorescent protein (GFP) and T4L. These and others have
been reviewed extensively elsewhere [31,32]. Briefly, polyhistidine
tags are routinely fused to recombinantly-produced membrane
proteins to facilitate rapid purification by metal chelate chro-
matography using Ni–NTA resins. In many cases, the tag is not
removed prior to crystallization trials, although protease cleavage
sites can be engineered into the expression plasmid if this is
desired [5]. GFP tags are used differently, typically to assess func-
tional yield or homogeneity of the purified recombinant protein
prior to crystallization trials. In the former case, caution must be
exercised because GFP tags remain fluorescent in eukaryotic cells
irrespective of whether the partner membrane protein is correctly
folded in the plasma membrane [33]. GFP is therefore an inappro-
priate marker to assess the folding status of recombinant mem-
brane proteins produced in yeast prior to extraction, although it
is still useful in analyzing the stability of a purified membrane pro-
tein by fluorescence size-exclusion chromatography [34]. Finally,
most GPCR crystal structures have been obtained using a fusion
protein strategy where the flexible third intracellular loop is
replaced by T4L, with modified T4L variants having been developed
to optimize crystal quality or promote alternative packing interac-
tions [8]. Overall, the precise combination and location (at either
terminus or within the protein sequence itself) of any tags needs
to be decided based upon their proposed use (for targeting, as an
epitope, for purification or as a tool to assess protein quality) and
the biochemistry of the recombinant membrane protein (since
the exact fusion site may have a major impact on protein yield
and quality).
3.3. Codon optimization
The sequence of an mRNA transcript is critically important in
determining the rate and accuracy of translation [35] meaning thatPlease cite this article in press as: S.J. Routledge et al., Methods (2015), http://optimal design of the corresponding DNA expression plasmid is
essential to the success of a recombinant protein production exper-
iment. Each organism is known to have a preference for some of
the 64 available codons over others, but the biological reason for
this is not yet clear. One idea is that each codon is decoded at a dif-
ferent rate: codons that are decoded quickly will be more resource
efficient [36], while slower decoding will allow time for proper
post-translational folding and translocation [37]. Another idea is
that different codons are read with different accuracy, which might
affect proteolysis and degradation [38]. Codon optimization
involves manipulating the sequence of an ORF in order to maxi-
mize its expression. Several companies (e.g. GeneArt and Gen-
Script) offer codon optimization services that account for codon
bias in the host cell, mRNA GC content and secondary structure
while minimizing sites such as internal ribosome entry sites or
premature polyA sites that may negatively affect gene expression.
However, there is no guarantee that recombinant protein yields
will be increased, as demonstrated for the production of two mem-
brane proteins in E. coli [39]. In contrast, careful codon optimiza-
tion of the mouse P-glycoprotein gene for expression in P.
pastoris led to substantially more recombinant protein compared
to expression from the wild-type gene [40] (Fig. 1k). It has been
proposed that the mRNA sequence around the translation start site
has a bigger influence on membrane protein yields than codon
choice in the rest of the ORF both in E. coli [39] and P. pastoris
[41] since strong mRNA structure in this region could affect trans-
lation initiation and therefore protein production [39]. The use of
degenerate PCR primers to optimize the codon sequence around
the start codon therefore offers one approach to improving the
expression plasmid [42].4. Optimization of the host cell
4.1. Saccharomyces cerevisiae
As mentioned in Section 2, a wide range of S. cerevisiae
resources are available, including comprehensive strain collections
from which potential expression hosts can be selected. These
resources are supported by a wealth of information in the Saccha-
romyces Genome Database (http://www.yeastgenome.org/). The
yeast deletion collections comprise over 21,000 mutant strains
with precise start-to-stop deletions of the approximately 6000 S.
cerevisiae ORFs [43]. The collections include heterozygous and
homozygous diploids as well as haploids of bothMATa andMATa
mating types. Individual strains or the complete collection can be
obtained from Euroscarf (http://web.uni-frankfurt.de/fb15/mikro/
euroscarf/) or the American Type Culture Collection (http://www.
atcc.org/). Complementing this, Dharmacon sells the Yeast Tet-
Promoters Hughes Collection (yTHC) with 800 essential yeast
genes under control of a tetracycline-regulated promoter that per-
mits experimental regulation of essential genes. A number of
specifically-engineered S. cerevisiae strains also exist including
those with ‘‘humanized” sterol (see Section 4.3) and glycosylation
pathways [44]. Notably, protease-deficient strains are a
consistently-popular choice in membrane protein structural biol-
ogy projects (Table 2).
Use of specific strains from these collections offers the potential
to gain mechanistic insight into the molecular bottlenecks that
preclude high recombinant protein yields; we and others have
used transcriptome analysis to guide strain selection. In an early
study we were able to identify genes that were up-regulated under
high yielding conditions for our target membrane protein (the
yeast glycerol facilitator, Fps1p) but down-regulated under low
yielding conditions or vice versa [45]. This enabled us to select four
high yielding strains: srb5D, spt3D, gcn5D and yTHCBMS1. The usedx.doi.org/10.1016/j.ymeth.2015.09.027
Table 2
Examples of protease-deficient S. cerevisiae strains used in structural biology projects.
Membrane protein Host species S. cerevisiae production strain Resolution (Å) Reference
H+-translocating pyrophosphatase (H+-PPase) Vigna radiate BJ2168 (MATa leu2 trp1 ura3-52 pep4-3 prb1-1122 prc1-407
gal2)
2.35 [107]
Phosphate transporter (PiPT) Piriformospora indica DSY-5 (MATa leu2 trp1 ura3-52 his3 pep4 prb1) 2.9 [108]
CAAX protease, Ste24p Saccharomyces mikatae BJ54060 (MATa ura3-52 trp1 lys2-801 leu2-D1 his3-D200 pep4::
HIS3 prb1-D1 6R can1 GAL+)
3.1 [109]
Lipid scramblase, TMEM16 Nectria haematococca FGY217 (MATa, ura3-52, lys2D201, pep4D) 3.3 [94]
Monoamine oxidase A Homo sapiens BJ2168 (MATa leu2 trp1 ura3-52 prc1-407 ptb1-1122 pep3-3) 2.2 [110]
S.J. Routledge et al. /Methods xxx (2015) xxx–xxx 5of the spt3D strain resulted in the largest yields of Fps1p in shake-
flasks (over 40-fold compared to wild-type cells). When the
yTHCBMS1 strain was cultured in the presence of 0.5 lg/ml doxy-
cycline (to regulate the essential gene, BMS1, which is involved in
the biogenesis of the 40S ribosomal subunit [46]), yields were
increased by 30-fold in shake-flasks and over 70-fold in bioreactors
compared with wild-type cells [47]. Using the strains srb5D and
gcn5D, Fps1p yields were increased 5- and 10-fold over wild-
type, respectively (Fig. 2). While these strains were originally
selected to optimize Fps1p yields, we also noted generic advan-
tages in that functional yields of the adenosine A2A receptor and
soluble GFP could be doubled using them [47]. This suggests that
both general and target-specific effects are likely to occur during
recombinant protein production in yeast (and indeed in any
recombinant host cell). It would be desirable to be able to distin-
guish between the two, but this remains challenging because of
the limited number of studies that have been done, including those
in yeast.
Specific metabolic pathways have been targeted in order to
increase functional recombinant protein yields in yeast cells. For
example, exploiting the global cellular stress response to misfolded
proteins has been investigated as a route to improving functional
yields of recombinant proteins for structural studies [48]; it has
even been argued that exposure to mild stress may enhance toler-
ance to a future stressful stimulus [49] such as that imposed during
recombinant protein production. A recent study of recombinant
GPCR production in S. cerevisiae demonstrated that mislocalized
proteins were associated with the endoplasmic reticulum chaper-
one, BiP [50], providing opportunities to regulate the chaperone0 
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Fig. 2. Relative yields of the membrane protein, Fps1p, in high yielding strains. Yeast w
from immunoblots where the error bars represent standard error of the mean (SEM; n
significance of the relative yields of Fps1p in the different production strains compar
***P 6 0.001 and ****P 6 0.0001.
Please cite this article in press as: S.J. Routledge et al., Methods (2015), http://network. The unfolded protein response (UPR) and the heat shock
response (HSR) have also been examined; tuning expression levels
to avoid or minimize UPR induction has previously been shown to
increase functional membrane protein yields [51], while the HSR
activates chaperones and the proteasome in order to relieve stress.
HSR up-regulation has specifically been used to increase recombi-
nant yields of soluble a-amylase in S. cerevisiae, but did not
increase the yield of a recombinant human insulin precursor
[52]. Overall, studies such as these demonstrate that the manipula-
tion of stress responses may influence recombinant protein yields
in yeast (and other organisms), but that the magnitude of any
effect is protein specific.
4.2. Pichia pastoris
P. pastoris expression plasmids are usually integrated into the
yeast genome to produce a stable production strain. Since it is
not possible to precisely control the number of copies that inte-
grate, the optimal clone must be selected experimentally. One
approach is to screen on increasing concentrations of antibiotic
(usually zeocin; Fig. 3) to obtain so-called ‘‘jackpot” clones.
Although the results in Fig. 3 suggest a correlation between the
copy number of the integrated expression cassette (as determined
by resistance to increasing zeocin concentrations) and the final
yield of recombinant protein, this is not always the case [53].
Sometimes clones with lower copy numbers are more productive,
suggesting that the cellular machinery is overwhelmed in jackpot
clones (resulting in misfolded or degraded protein). Consistent
with this idea, adenosine A2A receptor yields were increasedWT
yTHCBMS1 
yTHCBMS1 0.5 µg/mL 
doxycycline
srb5Δ
gcn5Δ
spt3Δ
****
ere grown in shake flasks in 2  CBS until an OD600 4. The data are relative yields
= 3). Data were analysed using a one-way ANOVA (P < 0.0001). Asterisks show the
ed to wild-type, as determined by a Dunnett’s multiple comparison test, where
dx.doi.org/10.1016/j.ymeth.2015.09.027
Fig. 3. Screening and scale-up of a P. pastoris production strain. A pPICZa-based
expression plasmid containing the human AQP1 gene was integrated into P. pastoris
strain X33. Colonies were selected on YPD plates containing 100, 250 and 500 lg/ml
zeocin. Eight colonies were isolated from each plate and cultured in BMGY to
OD600 = 1. Expression was induced by culturing the cells in BMMY for 24 h. Protein
production was assessed by immunoblot of 100 lg total membrane protein per
lane; the images indicate the variation in yield for the different colonies under
different zeocin selection pressures. Molecular weight markers are shown in kDa.
6 S.J. Routledge et al. /Methods xxx (2015) xxx–xxx1.8-fold when the corresponding gene was co-expressed in
P. pastoris with the stress-response gene HAC1 [54]; Hac1 drives
transcription of UPR genes (see also Section 4.1).
In contrast to the situation in S. cerevisiae, many fewer P. pas-
toris strains are available in which to integrate the expression plas-
mid for the generation of a recombinant production strain. The
wild-type strain, X33, the histidine auxotroph GS115, and the
slow-methanol-utilization strain KM71H, have all been used to
produce membrane proteins for structural studies [5]. Protease-
deficient strains such as SMD1163, which lacks proteinase A and
proteinase B, are also available. The structures of recombinant
membrane proteins produced using P. pastoris that were published
in 2014 and 2015 (Fig. 1) were all produced in one of the three
mutant strains, SMD1163, KM71H and GS115 [3]. Notably produc-
tion of human aquaporin 2 was actually done using an engineered
GS115 strain in which the native aquaporin gene, AQY1, was
deleted.
In all these strains, P. pastoris (like S. cerevisiae) post-
translationally glycosylates membrane proteins by adding core
(Man)8-(GlcNAc)2 groups, but not the higher-order structures
found in humans and other mammals; compared to S. cerevisiae,
the mannose chains also tend to be shorter. However, the effects
of these non-native modifications are not necessarily detrimentalPlease cite this article in press as: S.J. Routledge et al., Methods (2015), http://and need to be assessed for each individual protein [55]. Indeed,
the high-resolution structure of a glycosylated form of the
Caenorhabditis elegans P-glycoprotein (using recombinant protein
produced in P. pastoris) demonstrates that yeast glycosylation does
not necessarily hinder crystal formation [56]. Nonetheless, in order
to overcome potential bottlenecks in producing, purifying, charac-
terizing and crystallizing human proteins in yeast, engineered
strains have been developed including strains with ‘‘humanized”
glycosylation [57,58] and sterol pathways (see Section 4.3).4.3. Engineering the yeast membrane for membrane protein
production
The yeast membrane differs in composition from that of
mammalian membranes. This is likely to be highly relevant to
subsequent structural and functional studies of recombinant mem-
brane proteins produced in yeast because lipids have a particularly
important role in the normal function of membrane proteins; they
contribute to membrane fluidity and may directly interact with
membrane proteins.
In an attempt to ‘‘humanize” the yeast membrane, yeast strains
have been developed that synthesize cholesterol rather than the
native yeast sterol, ergosterol. This was achieved by replacing the
ERG5 and ERG6 genes of the ergosterol biosynthetic pathway with
the mammalian genes DHRC24 and DHRC7 [59–61], respectively.
The gene products of DHRC7 and DHRC24 were identified as key
enzymes that saturate sterol intermediates at positions C7 and
C24 in cholesterol (but not ergosterol) synthesis (Fig. 4). Erg5p
introduces a double bond at position C22 and Erg6p adds a methyl
group at position C24 in the ergosterol biosynthetic pathway and
therefore competes with the gene product of DHRC24 for its
substrate.
The yeast tryptophan permease, Tat2p, was unable to function
in a yeast strain producing only ergosterol intermediates (instead
of ergosterol), but in a cholesterol-producing strain activity was
recovered to almost wild-type levels. Localization to the plasma
membrane also appeared to correlate with the function of Tat2p
[59]. The yeast ABC transporter, Pdr12p, although correctly local-
ized to the plasma membrane, was inactive in a cholesterol-
producing strain because of the lack of the key methyl group at
position C24 [59] (Fig. 4). A similar scenario was observed with
the function of yeast Can1p: the protein was localized to the
plasma membrane regardless of the sterol produced, but function
was lost when ergosterol production was disrupted [59]. The
native yeast GPCR, Ste2p, which is involved in signal transduction,
partially retained its function when cholesterol was produced
instead of ergosterol. The agonist of Ste2p, MFa, retained potency
on this receptor in both wild-type and cholesterol-producing
strains. However, the efficacy appeared to be only half of that
observed in the wild-type strain [60]. A positive outcome was
observed when the human Na,K-ATPase a3b1 isoform was
expressed in a cholesterol-producing P. pastoris strain [61]: there
was an improvement in recombinant yield and radio-ligand bind-
ing on intact cells, with the number of ligand binding sites in the
cholesterol-producing strain increasing 2.5- to 4-fold compared
to wild-type and protease deficient strains, respectively, both of
which are ergosterol-containing [61].
Overall, studies on native yeast membrane proteins suggest that
cell viability is not impaired in ‘‘humanized” yeast cells, although
growth rates and densities are somewhat affected. However, this
is likely to be an acceptable trade-off in return for higher yields
of functional protein. Since a relatively small number of heterolo-
gous membrane proteins have been produced in cholesterol-
producing yeast strains to date, potential exists to further optimize
functional yields by using them.dx.doi.org/10.1016/j.ymeth.2015.09.027
Fig. 4. Humanization of the yeast sterol pathway. The key products and intermediates in the mammalian cholesterol and fungal ergosterol biosynthesis pathways are shown.
The pathways share common precursors, labeled in blue font, such as zymosterol which undergoes several chemical reactions (3 in yeast and 2 in mammalian cells) before
being converted to cholesta-5,7,24(25)-trienol, which is effectively the branching point of the two pathways. The red circles and arrows indicate where the mammalian
enzymes, DHCR7 and DHCR24, saturate bonds at positions 7 and 24 in cholesterol synthesis, respectively; they were identified as the enzymes required for cholesterol
production in yeast. Yeast Erg6p and Erg5p of the ergosterol synthesis pathway, whose actions are shown in green, were deleted simultaneously with the introduction of the
mammalian genes mentioned above because these enzymes would interfere with cholesterol synthesis in yeast. Erg4p, whose action is circled in grey, is the last enzyme in
the pathway; since its substrate is the product of Erg6p catalysis, it does not interfere with cholesterol synthesis.
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Recovering functional protein from recombinant host cells is
dependent upon their capacity to synthesize an authentically-
folded polypeptide. This requires the proper functioning of the
transcription, translation and folding pathways [62]. During a
recombinant protein production experiment, the maintenance
and processing of an expression plasmid places a substantial
metabolic burden on a cell, which means that these pathways must
operate under abnormally stressful conditions [3]. A popular strat-
egy to mitigate this burden is to decrease culture temperature;
however, transcription, translation, polypeptide folding rates and
membrane composition are also affected by low temperature
stress [63]. This probably explains why increased yields are not
always observed experimentally using that approach. Furthermore,
many other variables are likely to affect yields including the
composition of the growth medium, the pH and oxygenation of
the culture, the inducer concentration and the point of induction.5.1. Medium composition
Yeast cells grow quickly in complex or defined media; the
selection and composition of suitable broths have been discussed
elsewhere [12]. While higher yields are typically achieved in com-
plex media, more control is possible in selective media, such as the
ability to incorporate selenomethionine for anomalous dispersion
phasing [64] in both S. cerevisiae [65] and P. pastoris [66].
The transcriptional and translational machinery of a cell
respond to its growth rate, which is strongly affected by nutrient
availability [3]. For example, several inducible and constitutive
S. cerevisiae promoters have recently been characterised following
growth on different carbon sources (glucose, sucrose, galactose and
ethanol) and across the diauxic shift in glucose batch cultivation
[22]. The study demonstrates that constitutive promoters differ
in their response to different carbon sources and that expression
under their control decreases as glucose is depleted and cells enter
the diauxic shift [22]. Changes in nutrient source have also been
found to alter the transcriptome and the global translational capac-
ity of P. pastoris [25]. As discussed in Section 3.1, when P. pastoris
cells were cultured in methanol, the majority of the total mRNA
pool was associated with two or more ribosomes per mRNA (and
therefore designated as highly-translated). Methanol is used to
induce protein production under the control of PAOX1 in this yeast,
suggesting that high recombinant protein yields may be associated
with the global response of P. pastoris to methanol as well as
promoter activity [26].5.2. Additives
Several small molecules, sometimes referred to as chemical
chaperones, have been investigated for their ability to enhance
functional membrane protein yields. Specific improvements in
yield have been reported following addition to recombinant yeast
cultures of dimethyl sulphoxide (DMSO), glycerol, histidine and
protein-specific ligands [67–69]. The effects of antifoams on pro-
tein yield, which are added to prevent foaming in bioreactor cul-
tures, are discussed separately in Section 5.3.
The solvent DMSO has numerous biological applications, and is
routinely used as a cryoprotectant and a drug vehicle [70]. Addi-
tion of DMSO to yeast cultures producing membrane proteins has
been reported to have a positive effect on yield [71]. DMSO added
at 2.5% v/v more than doubled the yield of 9 GPCRs (out of a panel
of 20) produced in P. pastoris, with improvements of up to 6-fold
[72]. In another study, the production in S. cerevisiae of a range
of transporters fused to GFP was enhanced on average by 30%Please cite this article in press as: S.J. Routledge et al., Methods (2015), http://following DMSO addition [73]. However, DMSO has also been
reported to have no effect or, in some cases, negative effects upon
membrane protein yields [72,74]. The underlying mechanisms are
incompletely understood; DMSO is known to increase membrane
permeability and cross membranes itself [70]. It has also been
shown to upregulate the transcription of genes involved in lipid
biosynthesis and increase phospholipid levels in S. cerevisiae [75].
When DMSO is added with stabilizing ligands, it may therefore
improve the ability of these compounds to pass through the mem-
brane and reach receptors in compartments within the cell [72].
Glycerol has been added to S. cerevisiae cultures producing
human P-glycoprotein; at 10% v/v, yields were improved by up to
3.3-fold [67]. Glycerol is not as membrane-permeable as DMSO
[70], so is thought to exert its effects by stabilizing protein confor-
mation [67,69]. However, in another study, glycerol addition had a
negative impact upon the yields of several membrane proteins
produced in S. cerevisiae [73].
When producing recombinant membrane proteins such as
GPCRs, ligands may be added at saturating concentrations to boost
yields. Functional yields of GPCRs such as the b2-adrenergic
receptor were tripled, the 5HT5A receptor doubled [76] and the
adenosine A2A receptor doubled [77] by adding receptor-specific
ligands. An optimization study demonstrated that addition of
ligand could improve functional yields of 18 out of 20 GPCRs, with
increases of up to 7-fold. However, a decrease in Bmax was observed
for two of the receptors investigated [72]. It is thought that ligands
able to pass through the plasma membrane may bind to receptors
as they fold during biosynthesis, thereby stabilizing them in the
correctly-folded state. As a result, the level of functional receptors
expressed at the plasma membrane is increased [78].
The amino acid, histidine, has been shown to double yields of
some GPCRs when added to cultures at 0.04 mg/mL. Notably, its
addition positively influenced fewer receptors than other additives
such as DMSO [72]. Histidine addition did not have any effect upon
the growth of the cells; instead it has been suggested that
improved protein yields may result from its ability to protect yeast
from oxidative stress [72,79].
Overall, it is clear that the use of a range of additives has
improved recombinant membrane protein yields for diverse tar-
gets. In some cases additive effects have been synergistic, while
in others their addition has been detrimental [72]. It is therefore
important to systematically investigate the effects of additives on
a case-by-case basis.
5.3. Other factors: temperature; pH; oxygenation
Membrane protein production is often done in bioreactors in
order to obtain the large quantities of protein required for crystal-
lization trials. Use of bioreactors enables the tight control of critical
parameters, such as culture temperature, pH and the level of
dissolved oxygen, thereby enabling the design of highly-
reproducible bioprocesses. The most efficient way to select the
optimal combination of these parameters is to use a design of
experiments (DoE) approach [80]. DoE applies a structured test
design to determine how combining input parameters set at differ-
ent levels (e.g. pH set at 5, 6, 7; temperature set at 20 C, 25 C,
30 C; dissolved oxygen concentration set at 30%, 40%, 50%) affects
the output (recombinant protein yield). This efficient test design
means that all experimental combinations do not need to be tested
in order to derive the empirical relationship between the input
parameters and protein yield in the form of a deterministic equa-
tion. The DoE approach is therefore a highly efficient way to obtain
a quantitative understanding of how each factor and its interaction
with all other factors affect final protein yield [80]. While this strat-
egy is ideally executed in a bioreactor format, even in shake flasks
yields can be improved by careful control of culture conditions [81].dx.doi.org/10.1016/j.ymeth.2015.09.027
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especially of P. pastoris cells, is appropriate oxygenation. This is
achieved by vigorous stirring and (if necessary) sparging of gases,
which usually leads to foaming. The addition of chemical antifoam-
ing agents is therefore required to manage and prevent the forma-
tion of foam. As additives to the process, these chemicals can
affect both host cells and the recombinant proteins being produced;
yields can be affected by the type of antifoam used, the concentra-
tion added, and whether production is undertaken in small shake
flasks or in larger-scale bioreactors ([82] and unpublished data).
Although the biological effects of antifoams are not well under-
stood, they have been shown to affect the volumetric mass oxygen
transfer coefficient (kLa) [83], influence growth rates of yeast [82,84]
and are thought to alter membrane permeability [85]. While it was
possible to more than double the yield of soluble GFP secreted by P.
pastoris cells following the optimization of antifoam addition, the
same conditions had detrimental effects on the functional yield of
a recombinant GPCR produced in yeast (unpublished data). These
findings highlight the importance of investigating the effects of
antifoam addition; this often disregarded experimental parameter
can significantly affect recombinant protein yields.
5.4. Induction conditions
In Section 3.1, we highlighted the fact that most recombinant
expression systems employed in structural biology pipelines
depend upon strong, inducible promoters. All promoters are
known to vary in activity over time as well as in response to differ-
ent carbon sources, which means that the timing of induction (and
the concentration of the inducer) can be critical in obtaining the
highest yields of functional protein; these parameters must be
empirically determined. The response of a series of inducible S.
cerevisiae promoters to different carbon sources has been studied
[22] providing a framework for these types of experiments. We
previously demonstrated the major impact of the induction regime
on the yield of secreted GFP from P. pastoris cultures, showing the
importance of matching the composition of the methanol feed-
stock to the metabolic activity of the cells [86]. PAOX1 is induced
on methanol; however, when glucose (which has been shown to
repress AOX1 expression) was the pre-induction carbon source,
the adenosine A2A receptor and GFP were still produced in the
pre-induction phases of bioreactor cultures [26]. This study also
reveals that a range of recombinant membrane proteins can be
detected in the pre-induction phases of P. pastoris cultures when
grown in bioreactors, but not shake-flasks. The results of all these
investigations suggest that a DoE approach to selecting and opti-
mizing induction phase conditions might be a particularly effective
method of maximizing recombinant protein yields.
6. Extraction and solubilization of functional protein from yeast
cells
The first steps in isolating a recombinant membrane protein are
to break open the host cells and harvest the membranes. In yeast
this requires breaking the cell wall, which needs harsher condi-
tions than those typically used for insect, mammalian or E. coli
cells. Typical methods for achieving this include high pressure
(French Press or Emulsiflex-C3) or homogenization using glass
beads shaken at high frequency followed by differential centrifuga-
tion [87].
6.1. Detergent-based solubilization of recombinant membrane
proteins
In isolating a recombinant membrane protein from yeast
membranes [87], the goal is to maintain structural integrity andPlease cite this article in press as: S.J. Routledge et al., Methods (2015), http://functionality. Depending on the protein target, this can be an
extremely difficult task. However approaches are available to opti-
mize the extraction process and the environment into which the
target protein is being transferred.
Traditionally, detergents have been used for membrane protein
extraction, purification and crystallization; the general principles
have been reviewed extensively elsewhere [7,88]. Popular
detergents include the non-ionic n-octyl-b-D-gluocopyranoside
(b-OG), n-decyl-b-D-maltopyranoside (DM) and n-dodecyl-b-D-
maltopyranoside (DDM) [89]. Interestingly, the most commonly-
used detergents to date are the same for yeast as for other expres-
sion systems, despite the differences in membrane composition.
Optimization of detergent and buffer conditions must be done for
each individual target membrane protein by assessment of protein
stability and monodispersity. Unfortunately, membrane protein
aggregation is a relatively common occurrence in these studies
since detergents do not provide an exact mimic of the lipid envi-
ronment in which the protein natively resides. Alternative amphi-
philes have been designed to overcome these limitations and
include novel compounds such as maltose neopentyl glycol
(MNG) [90]. It has been suggested that for some target membrane
proteins, MNG provides increased protein stability in comparison
to detergents such as DM [91].
One useful technique to assess membrane protein stability prior
to crystallization trials exploits a thiol-specific fluorochrome,
N-[4-(7-diethylamino-4-methyl-3-coumarinyl)phenyl]maleimide
(CPM), which enables the investigator to assess the thermal stabil-
ity of a recombinant membrane protein in a high-throughput for-
mat, therefore requiring small amounts of purified material [92].
In order to use this assay, the target membrane protein must have
cysteine residues buried within the hydrophobic interior. Such
residues bind thiol-specific CPM upon temperature-induced pro-
tein unfolding. CPM is essentially non-fluorescent until it reacts
with a cysteine residue; therefore fluorescence can be recorded
over time to determine the rate of protein unfolding. The influence
of detergent type and concentration, salt concentration, pH, glyc-
erol content and lipid addition on stability can all be investigated.
Several studies have found a correlation between protein stability
(as determined by the CPM assay) and the likelihood of obtaining
well-ordered crystals for high resolution structure determination
[93].
6.2. Functional reconstitution of detergent-solubilized recombinant
membrane proteins
When determining the structure of a protein it is important to
demonstrate that it is functional. For many membrane proteins,
measuring function in the detergent-solubilized state can be diffi-
cult, either due to detergent effects (e.g. stripping away interacting
lipids, lack of lateral pressure, protein denaturation) or because
both ‘sides’ of the membrane are accessible. Therefore reconstitu-
tion of detergent-solubilized proteins into proteoliposomes is
needed. Typically this involves the following steps: preparation
of liposomes comprised of the desired lipids; destabilization of
the liposomes with a detergent; mixing of detergent-purified pro-
tein with the liposomes; and removal of detergent using methods
such as adsorption onto Bio-Beads SM-2 resin [18,94] or dialysis
[95]. Several proteins expressed in S. cerevisiae [18,94] or P. pastoris
[95–97] have been reconstituted into proteoliposomes and studied,
showing that proteins produced in yeast are fully functional and
comparable to those expressed in other cell systems.
6.3. Detergent-free methods – the emergence of SMALPs
Although all crystal structures of membrane proteins to date,
including those synthesized in yeast, have used detergents fordx.doi.org/10.1016/j.ymeth.2015.09.027
Fig. 5. SMALP-encapsulated membrane protein is more stable than its detergent-solubilized variant, and can easily be concentrated. (a) Stability over time. P-glycoprotein-
His12 (Pgp) was extracted from membranes using either 2.5% (w/v) SMA or 2% (w/v) b-OG (OG), and purified using Ni2+-NTA affinity chromatography. Samples of purified
protein were analysed by SDS–PAGE and stained using Instant Blue. Following storage of the purified protein at 4 C for 2 days, further samples were analyzed. The SMA-
purified sample appears very similar, but the b-OG-purified sample shows significant breakdown over this time. (b) Thermostability. Unfolding of purified Pgp was monitored
by fluorescence labeling with CPM after a 10 min incubation at various temperatures. OG-solubilized Pgp was 50% unfolded at a temperature of 37 C, whereas SMALP-
encapsulated Pgp was 50% unfolded after 10 min at 50 C. (c) Purified SMALP-encapsulated Pgp at a concentration of 35 lg/ml (dilute) was concentrated using an Amicon
Ultra centrifugal concentrator (with a molecular weight cut-off of 30 kDa) to 1 mg/mL (conc), without significant loss or denaturation of protein. (d) Specific binding of [3H]
ZM241385 (10 nM) to the adenosine A2A receptor, extracted either with DDM or SMA in the absence or presence of CHS. Data are mean ± SEM, n = 3. (e) Schematic of the
structure of SMA.
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detergents is not without problems. As mentioned in Section 6.1,
screening for conditions and detergents that effectively extract
the protein yet retain structure and stability can be difficult, time
consuming and expensive. The environment produced by a deter-
gent micelle does not fully mimic the lipid bilayer environment,
as not only does the bilayer provide lateral pressure to stabilize
the protein structure but interactions between the protein and
its annular lipids can affect protein function. Notably, the most
effective detergents for extraction are often not the best detergents
for crystal formation. Recently a new detergent-free method for
extraction of membrane proteins has emerged using SMA
co-polymers (Fig. 5). The SMA inserts into biological membranes
and forms small discs of lipid bilayer (10–12 nm) surrounded by
the polymer, termed SMALPs (SMA lipid particles) [9,10], also
known as lipodisqs [98] or native nanodiscs [11]. Membrane pro-
teins within the SMALPs retain their annular lipid bilayer environ-
ment [9,11,99], yet the particles are small, stable and water
soluble, allowing standard affinity chromatography methods to
be used to purify a protein of interest [11,99–102].
To date this approach has been successfully applied to a wide
range of transmembrane proteins from many different expression
systems including both S. cerevisiae [98,100] and P. pastoris [102],
for protein targets including GPCRs, ABC transporters and ion
channels. Proteins within SMALPs have been shown to retain func-
tional activity [11,98,100–102]. The small size of the particle and
lack of interference from the polymer scaffold mean the SMALPs
are ideal for many spectroscopic and biophysical techniques
[9,10,100,102,103]. Importantly for structural studies, SMALP-
encapsulated proteins have been found to be significantly more
thermostable, less prone to aggregation, and easier to concentrate
than detergent-solubilized proteins [11,100–102] (Fig. 5).Please cite this article in press as: S.J. Routledge et al., Methods (2015), http://The importance of maintaining the lipid bilayer environment
and lateral pressure is highlighted in Fig. 5d. When the adenosine
A2A receptor is extracted from P. pastoris membranes with deter-
gent (DDM), it is necessary to supplement with the cholesterol
analogue, cholesterol hemisuccinate (CHS), in order to retain any
binding activity. However when the SMA co-polymer is used to
extract the receptor, there is no requirement for CHS suggesting
that it is not the cholesterol per se that is required for function of
this protein, but some stabilizing interaction with lipids.
Although as yet, there are no reports of SMALP-encapsulated
proteins being used to generate protein crystals, they have been
used in both negative stain and cryo-single particle electron micro-
scopy [100,101]. With recent technological and analytical advances
within the field of electron microscopy the possibility of high res-
olution membrane protein structures using electron microscopy
has become a reality [104,105]; SMALPs offer the ability for these
structures to be obtained without stripping away the membrane
environment from a transmembrane protein.
7. Conclusions
Yeast has an important role to play in membrane protein struc-
tural biology projects; since S. cerevisiae and P. pastoris are partic-
ularly amenable to genetic study, new insight may emerge that can
lead to the design of improved experiments. One challenge is to
identify which experimental parameters discussed in Sections
3–5, above, should be the focus in devising a production trial for
a novel target. This is particularly demanding since these parame-
ters may affect both host-cell- and target-protein-specific
responses. Our understanding of the interlinked processes of tran-
scription, translation and protein folding offers new opportunities
to improve functional yields of recombinant membrane proteinsdx.doi.org/10.1016/j.ymeth.2015.09.027
S.J. Routledge et al. /Methods xxx (2015) xxx–xxx 11through strain selection and the choice of suitable culture condi-
tions using DoE (Section 5). Coupled with new approaches to
extraction and solubilization (Section 6), it is likely that the pace
of solving new membrane protein structures is set to increase in
the foreseeable future.
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